Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of Efiicacy, Tolerability & Safety of Sulopenem & Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro-metronidazole for Treatment of cIAI in Adults

NCT03358576 is registered in ClinicalTrials.gov with Iterum Therapeutics, International Limited as lead sponsor.

NCT NCT03358576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03358576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of Efiicacy, Tolerability & Safety of Sulopenem & Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro-metronidazole for Treatment of cIAI in Adults
Lead sponsor
Iterum Therapeutics, International Limited
Phase
Phase 3
Overall status
Completed
Start date
September 18, 2018
Completion date
October 2, 2019
Enrollment
674 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

intra abdominal infections